Release Date: June 15, 2023
Expiration Date: June 15, 2024

Target Audience
This activity has been designed for medical hematologists/oncologists, radiation oncologists, pathologists, surgical oncologists, fellows-in-training, oncology nurses, and allied health professionals committed to the diagnosis and treatment of lymphoma

Learning Objectives
At the conclusion of this activity, participants will be able to:

• Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma
• Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma
• Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data
• Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL
• Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma

ACCREDITATION AND CREDIT DESIGNATION

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Health Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.   


Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, the University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

The staff of the Center for Continuing Medical Education, Bio Ascend, and Meeting Achievements have disclosed that they have no relevant financial relationships with ACCME defined commercial interests.

Co-Chairs
Sonali M. Smith, MD, FASCO
Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Sonali Smith, MD, FASCO served as a consultant for Morphosys, Gilead, and BMS, and serves now as a consultant for ONO.

Andrew Evens, DO, MBA, MSc
Associate Vice Chancellor
Clinical Innovation & Data Analytics, Rutgers Biomedical and Health Sciences
System Director of Medical Oncology and Oncology Lead for RWJBarnabas-Rutgers
Medical Group, RWJBarnabas Health
New Brunswick, New Jersey

Andrew Evens, DO, MSc, FACP serves on the advisory board for Seattle Genetics and Epizyme, served in the past on advisory boards for Hutchmed, Incyte, and Daiichi Sankyo, and the data and safety monitoring board for Novartis and Pharmacyclics.

Timothy Fenske, MD, MS
Professor, Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin

Timothy Fenske, MD, MS serves as a consultant for Adaptive Biotechnologies, and Pharmacyclics. He serves as a speaker for AstraZeneca, Beigene, SeaGen, and Kite.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer
The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Genentech, Inc., Genmab US, Inc.,, Incyte, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc, Seagen

Technical Requirements

This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.